Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, Tolerability and Systemic Exposure of QR-110 in Subjects with Leber's Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Trial Profile

A Double-Masked, Randomized, Controlled, Multiple-Dose Study to Evaluate the Efficacy, Safety, Tolerability and Systemic Exposure of QR-110 in Subjects with Leber's Congenital Amaurosis (LCA) due to c.2991+1655A>G Mutation (p.Cys998X) in the CEP290 Gene

Planning
Phase of Trial: Phase II/III

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs QR 110 (Primary)
  • Indications Leber congenital amaurosis
  • Focus Registrational; Therapeutic Use
  • Acronyms ILLUMINATE
  • Sponsors ProQR Therapeutics
  • Most Recent Events

    • 29 Jan 2019 According to the ProQR Therapeutics, updates from the study announced in ProQR Vision 2023 strategy and will be presented at an R&D day event.
    • 29 Jan 2019 According to a ProQR Therapeutics media release, the company plans to complete pivotal program around year-end 2020 for submission of a New Drug Application (NDA) in the U.S. and a Marketing Authorization Application (MAA) in Europe in 2021.
    • 07 Jan 2019 According to a ProQR Therapeutics media release, the company has reached agreement with the U.S. Food and Drug Administration (FDA) on the design of this trial. The company anticipates top line results for base-case of 30 trial participants around year-end 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top